| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/31/2004 | EP1401484A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 03/31/2004 | EP1401483A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
| 03/31/2004 | EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 03/31/2004 | EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401473A2 Transporters comprising spaced arginine moieties |
| 03/31/2004 | EP1401469A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 03/31/2004 | EP1401468A2 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| 03/31/2004 | EP1401467A1 Alpha-fetoprotein peptides and uses thereof |
| 03/31/2004 | EP1401463A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 03/31/2004 | EP1401458A2 Composition consisting of phy906 and chemotherapeutic agents |
| 03/31/2004 | EP1401456A1 Method fron determining the efficacy of reverse cholesterol transport enhancing agents |
| 03/31/2004 | EP1401454A2 Use of corrinoids in the treatment of skin diseases |
| 03/31/2004 | EP1401453A2 Protease inhibitors |
| 03/31/2004 | EP1401452A1 Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease |
| 03/31/2004 | EP1401451A2 Quinazoline derivatives which promote the release of parathyroid hormone |
| 03/31/2004 | EP1401450A1 New use of a pyridazinone derivative |
| 03/31/2004 | EP1401449A1 Tetracyclic compounds as pde5-inhibitors |
| 03/31/2004 | EP1401448A1 Antibacterial treatment of osteoarthritis |
| 03/31/2004 | EP1401447A2 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith |
| 03/31/2004 | EP1401446A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
| 03/31/2004 | EP1401445A1 Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
| 03/31/2004 | EP1401444A1 Antihistamines for the treatment of nasal congestion and nasal obstruction |
| 03/31/2004 | EP1401443A1 Novel anti-infectives |
| 03/31/2004 | EP1401442A1 S-omeprazole (esomeprazole inclusion complex with cyclodextrins |
| 03/31/2004 | EP1401441A2 Allosteric adenosine receptor modulators |
| 03/31/2004 | EP1401440A1 Methods of use of fluoroquinolone compounds against bacteria |
| 03/31/2004 | EP1401439A1 Use of bicyclo compounds for treating alzheimer's disease |
| 03/31/2004 | EP1401438A1 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors |
| 03/31/2004 | EP1401437A1 Immune response modifiers for the treatment of periodontal disease |
| 03/31/2004 | EP1401436A1 Thiazolyl amides and their use as antiviral drugs |
| 03/31/2004 | EP1401435A1 Topical application of thiazolyl amides |
| 03/31/2004 | EP1401434A1 Modulators of peroxisome proliferator activated receptors (ppar) |
| 03/31/2004 | EP1401433A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 03/31/2004 | EP1401432A2 Imidazole derivatives for modulating sodium channels |
| 03/31/2004 | EP1401431A2 Human growth hormone antagonists |
| 03/31/2004 | EP1401429A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 03/31/2004 | EP1401427A2 Non-peptide gnrh agents, pharmaceutical compositions and methods for their uses, and processes for preparing them |
| 03/31/2004 | EP1401426A1 Ptpase inhibitors and method of using same |
| 03/31/2004 | EP1401425A1 Organometallic anti-tumour agent |
| 03/31/2004 | EP1401424A1 Carbamate compounds for use in preventing or treating psychotic disorders |
| 03/31/2004 | EP1401423A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| 03/31/2004 | EP1401422A2 Halogenated composition, method for preparing same and uses thereof |
| 03/31/2004 | EP1401421A1 Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor |
| 03/31/2004 | EP1401420A2 Perturbed membrane-binding compounds |
| 03/31/2004 | EP1401419A1 Benzenesulfonyl(thio)ureas for the treatment of septic shock and sirs |
| 03/31/2004 | EP1401418A2 Topical treatments using alkanolamines |
| 03/31/2004 | EP1401417A1 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 03/31/2004 | EP1401416A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 03/31/2004 | EP1401415A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 03/31/2004 | EP1401414A2 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 03/31/2004 | EP1401413A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 03/31/2004 | EP1401412A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 03/31/2004 | EP1401411A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 03/31/2004 | EP1401409A2 Stable powder inhalation dosage formulation |
| 03/31/2004 | EP1401408A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
| 03/31/2004 | EP1401406A2 Delivery of a bioactive material |
| 03/31/2004 | EP1401405A1 Oral pharmaceutical compositions with improved bioavailability |
| 03/31/2004 | EP1401404A2 Method of encapsulating an active substance |
| 03/31/2004 | EP1401402A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
| 03/31/2004 | EP1401401A2 Method for high through put screening using a small scale mill or microfluidics |
| 03/31/2004 | EP1401399A2 Pharmaceutical compositions containing polymer and drug assemblies |
| 03/31/2004 | EP1401398A1 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF |
| 03/31/2004 | EP1401397A2 Pharmaceutical formulation having a masked taste and method for the production thereof |
| 03/31/2004 | EP1401396A2 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 03/31/2004 | EP1401393A2 No-synthase inhibitor and use thereof |
| 03/31/2004 | EP1401392A1 Ascorbyl 2-hexadecanoate as a no-synthase inhibitor |
| 03/31/2004 | EP1401390A1 Use of at least one 10-hydroxy-2-decenoic acid derivative in compositions for treating the cutaneous signs of ageing |
| 03/31/2004 | EP1401389A2 Use of carnitine and/or one or more acyl-carnitines for producing cosmetic or dermatological preparations, which increase ceramide biosynthesis |
| 03/31/2004 | EP1401387A1 Carnitine and acyl-carnitines used in the treatment and prophylaxis of pigmentation disorders |
| 03/31/2004 | EP1401376A2 Colloidal metal compositions and methods |
| 03/31/2004 | EP1401351A2 Method for treating glaucoma vi |
| 03/31/2004 | EP1401294A1 Method for manufacturing of free-flowing powder containing water-dispersible sterols |
| 03/31/2004 | EP1401293A1 Calorically dense liquid oral supplement |
| 03/31/2004 | EP1401290A2 Composition for regulating animal growth, method of manufacture and use thereof |
| 03/31/2004 | EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap) |
| 03/31/2004 | EP1401277A1 Amenoacetonitrile compounds for controlling endoparasites |
| 03/31/2004 | EP1401275A1 Antiviral composition and treatment method |
| 03/31/2004 | EP1401268A1 Treatment or replacement therapy using transgenic stem cells delivered to the gut |
| 03/31/2004 | EP1401259A2 Delta-4 desaturase genes and uses thereof |
| 03/31/2004 | EP1372389A4 Virucidal compositions |
| 03/31/2004 | EP1370258A4 Peptide deformylase inhibitors |
| 03/31/2004 | EP1363623A4 Peptide deformylase inhibitors |
| 03/31/2004 | EP1305010B1 Dosage forms for treatment of oral mycoses |
| 03/31/2004 | EP1301501B1 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect |
| 03/31/2004 | EP1294742B1 Urokinase inhibitors |
| 03/31/2004 | EP1282620B1 Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
| 03/31/2004 | EP1282393A4 External application for enhancing the skin permeability of the active components therein |
| 03/31/2004 | EP1270599B1 Salmon-origin chondroitin sulfate |
| 03/31/2004 | EP1250156A4 Method for nucleic acid transfection of cells |
| 03/31/2004 | EP1232144B1 Novel il-8 receptor antagonists |
| 03/31/2004 | EP1230338A4 Continuous-flow method for preparing microparticles |
| 03/31/2004 | EP1212051A4 Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
| 03/31/2004 | EP1210072B1 Plastic films, especially for use in a dermal or transdermal therapeutic system |
| 03/31/2004 | EP1209166B1 Novel a-500359 derivatives |
| 03/31/2004 | EP1181294B1 Novel derivatives and analogues of galanthamin |
| 03/31/2004 | EP1177186B1 Ureas and their use as cell adhesion modulators |
| 03/31/2004 | EP1171132B1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol |
| 03/31/2004 | EP1135360B1 Novel 3-alkoxybenzylamine derivatives and their use as medicines for treating schizophrenia |
| 03/31/2004 | EP1126851B1 Pharmaceutical formulations in hydroxypropylmethylcellulose capsules |
| 03/31/2004 | EP1124543A4 Controlled release formulation for water soluble drugs |